Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.…
Definium Therapeutics: 3 Key Takeaways for Long-Term Investors
Definium Therapeutics (NASDAQ: DFTX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 105 employees.
The shares were at 28.34 USD on 20 November 2026, up 142.2% over 52 weeks. Its 52-week range is 10.46 USD to 49.70 USD: the price is 43.0% below the high and 170.8% above the low.
Its market capitalisation is 3.88B USD.
Definium Therapeutics reports return on equity of -55.3% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 1.01B USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. 18 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 72.83 USD is 157.0% above the current price. The next earnings report is expected on 4 March 2027.